TY - JOUR
T1 - Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers
T2 - An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study
AU - APS ACTION
AU - Gkrouzman, Elena
AU - Willis, Rohan
AU - Andrade, Danieli
AU - Tektonidou, Maria G.
AU - Pengo, Vittorio
AU - Ruiz-Irastorza, Guillermo
AU - Belmont, H. Michael
AU - Fortin, Paul R.
AU - Gerosa, Maria
AU - Signorelli, Flavio
AU - Atsumi, Tatsuya
AU - Branch, D. Ware
AU - Nalli, Cecilia
AU - Rodriguez-Almaraz, Esther
AU - Petri, Michelle A.
AU - Cervera, Ricard
AU - Knight, Jason S.
AU - Efthymiou, Maria
AU - Cohen, Hannah
AU - Bertolaccini, Maria Laura
AU - Erkan, Doruk
AU - Roubey, Robert
AU - Pons-Estel, Guillermo
AU - Giannakopoulos, Bill
AU - Krilis, Steve
AU - de Jesus, Guilherme
AU - Levy, Roger
AU - Balbi, Gustavo
AU - Clarke, Ann E.
AU - Skeith, Leslie
AU - Ji, Lanlan
AU - Zhang, Zhouli
AU - Yang, Chengde
AU - Shi, Hui
AU - Zuily, Stephane
AU - Wahl, Denis
AU - Andreoli, Laura
AU - Tincani, Angela
AU - Chighizola, Cecilia B.
AU - Meroni, Pierluigi
AU - Cheng, Chunyan
AU - Pazzola, Giulia
AU - Sciascia, Savino
AU - Foddai, Silvia
AU - Radin, Massimo
AU - Davis, Stacy
AU - Amengual, Olga
AU - Uthman, Imad
AU - Limper, Maarten
AU - Gonzalez, Emilio
N1 - Publisher Copyright:
© 2023 United States & Canadian Academy of Pathology
PY - 2023/6
Y1 - 2023/6
N2 - Several antiphospholipid antibody (aPL) profiles (“triple” and lupus anticoagulant [LA] positivity) are associated with a higher risk for clinical manifestations of antiphospholipid syndrome (APS). Further risk is correlated with higher levels of anticardiolipin antibody (aCL) and anti-β2 glycoprotein-I antibody (aβ2GPI), and with aPL persistence. Given that the 3 aPL tests detect partially overlapping sets of antibodies, the primary goal of this study was to characterize the associations among aPL tests using AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) core laboratory data. The APS ACTION Registry includes annually followed adult patients with positive aPL based on the Revised Sapporo Classification Criteria. We analyzed baseline and prospective core laboratory data of the registry for associations among aPL tests using the Spearman rank correlation with Bonferroni-adjusted significance level for multiple comparisons. An aPL Load was calculated based on 6 tests (aCL IgG/IgM/IgA and aβ2GPI IgG/IgM/IgA); a receiver operating characteristic curve was used to evaluate the diagnostic performance of the aPL Load in predicting LA positivity. In 351 patients simultaneously tested for LA, aCL, and aβ2GPI, the frequency of moderate-to-high (≥40 U) titers of aCL and aβ2GPI IgG/IgM/IgA was higher in patients who were positive for LA vs those who were negative. An aPL Load was calculated for each patient to assess the overall aPL burden. For every 1-point increase in the aPL Load, the possibility of a positive LA test increased by 32% (odds ratio, 1.32; 95% CI, 1.2-1.5; P <.001). Based on core laboratory data from a large international registry, most aPL enzyme-linked immunosorbent assay ≥40 U and a high calculated aPL Load combining 6 aPL enzyme-linked immunosorbent assays were predictive of a positive LA. These data suggest that the combined quantitative burden of aPL may provide a mechanistic explanation of a positive LA.
AB - Several antiphospholipid antibody (aPL) profiles (“triple” and lupus anticoagulant [LA] positivity) are associated with a higher risk for clinical manifestations of antiphospholipid syndrome (APS). Further risk is correlated with higher levels of anticardiolipin antibody (aCL) and anti-β2 glycoprotein-I antibody (aβ2GPI), and with aPL persistence. Given that the 3 aPL tests detect partially overlapping sets of antibodies, the primary goal of this study was to characterize the associations among aPL tests using AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) core laboratory data. The APS ACTION Registry includes annually followed adult patients with positive aPL based on the Revised Sapporo Classification Criteria. We analyzed baseline and prospective core laboratory data of the registry for associations among aPL tests using the Spearman rank correlation with Bonferroni-adjusted significance level for multiple comparisons. An aPL Load was calculated based on 6 tests (aCL IgG/IgM/IgA and aβ2GPI IgG/IgM/IgA); a receiver operating characteristic curve was used to evaluate the diagnostic performance of the aPL Load in predicting LA positivity. In 351 patients simultaneously tested for LA, aCL, and aβ2GPI, the frequency of moderate-to-high (≥40 U) titers of aCL and aβ2GPI IgG/IgM/IgA was higher in patients who were positive for LA vs those who were negative. An aPL Load was calculated for each patient to assess the overall aPL burden. For every 1-point increase in the aPL Load, the possibility of a positive LA test increased by 32% (odds ratio, 1.32; 95% CI, 1.2-1.5; P <.001). Based on core laboratory data from a large international registry, most aPL enzyme-linked immunosorbent assay ≥40 U and a high calculated aPL Load combining 6 aPL enzyme-linked immunosorbent assays were predictive of a positive LA. These data suggest that the combined quantitative burden of aPL may provide a mechanistic explanation of a positive LA.
KW - anticardiolipin
KW - antiphospholipid antibodies
KW - antiphospholipid syndrome
KW - lupus anticoagulant
UR - http://www.scopus.com/inward/record.url?scp=85162792350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162792350&partnerID=8YFLogxK
U2 - 10.1016/j.labinv.2023.100147
DO - 10.1016/j.labinv.2023.100147
M3 - Article
C2 - 37044248
AN - SCOPUS:85162792350
SN - 0023-6837
VL - 103
JO - Laboratory Investigation
JF - Laboratory Investigation
IS - 6
M1 - 100147
ER -